Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (GB:0J9P)
LSE:0J9P
0J9P Stock Chart & Stats
Day’s Range― - ―
52-Week Range$53.61 - $83.54
Previous CloseN/A
Volume2.48K
Average Volume (3M)383.00
Market Cap
$13.79B
Enterprise Value$14.92B
Total Cash (Recent Filing)$2.41B
Total Debt (Recent Filing)$43.12M
Price to Earnings (P/E)217.1
Beta0.47
Next Earnings
Aug 05, 2025EPS Estimate
1.4Last Dividend Ex-Date
Mar 15, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)1.16
Shares Outstanding193,569,930
10 Day Avg. Volume660
30 Day Avg. Volume383
Financial Highlights & Ratios
PEG Ratio-0.81
Price to Book (P/B)4.08
Price to Sales (P/S)0.00
P/FCF Ratio19.99
Enterprise Value/Market Cap1.08
Enterprise Value/Revenue0.90
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda12.78
Forecast
1Y Price Target
$75.00Price Target Upside6.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
Incyte News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyInitial data for ‘989 showed clear signs of platelet count normalization without signs of thrombocytopenia, with correlated significant VAF reduction indicating on-target effects.
Competitive PositioningThe positive phase 3 data in hidradenitis suppurativa gives confidence in competitive positioning, noting the rapid onset of response and pain reduction as clear differentiators.
Pipeline PotentialThe company is encouraged by the multiple shots on goal for potential approval before or around the expected Jakafi loss of exclusivity.
Bears Say
Regulatory ChallengesThe anticipated accelerated approval path for single-agent INCB123667 appears challenged given the less than 25% confirmed overall response rate and less than 4 months median duration of response.
Safety ConcernsSafety and tolerability concerns, including secondary malignancy risk, remain a class-specific issue dampening investor enthusiasm.
Options Prices
Currently, No data available
---
Ownership Overview
15.68% Insiders
22.48%
Mutual Funds
0.16% Other Institutional Investors
36.59% Public Companies and Individual Investors
0J9P FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest share price was $53.61 and its highest was $83.54 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $13.79B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Aug 05, 2025 which is in 46 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Apr 29, 2025. The company reported $1.16 earnings per share for the quarter, beating the consensus estimate of $0.978 by $0.182.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Incyte Corp dividends here
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.4.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 193,569,930 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $1.16 in its last earnings report, beating expectations of $0.978. Following the earnings report the stock price went up 3.011%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in GB:0J9P
Incyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$75.00 (6.91% Upside)
$75.00 (6.91% Upside)
Blogger Sentiment
Bullish
GB:0J9P Sentiment 85%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.76%
12-Months-Change
Fundamentals
Return on Equity
0.47%
Trailing 12-Months
Asset Growth
-19.43%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
0J9P Company Deck
0J9P Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong financial performance with significant revenue growth, successful product launches, and positive R&D progress. While there are potential challenges related to inventory management and competitive pressures, the overall sentiment remains optimistic due to the company's robust cash position and strategic planning.Read More>0J9P Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
0J9P Stock 12 Month Forecast
Average Price Target
$75.00
▲(6.91%Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
United Therapeutics
―
Ascendis Pharma
―
Genmab
―